Faron Announces Publication of Full Analysis from Phase 1/2

Bexmarilimab monotherapy shows efficacy in achieving disease control and prolonged survival in late-stage metastatic solid tumorsCLEVER-1 targeting is safe and well-tolerated with no serious adverse effectsBexmarilimab induced macrophage activation and increased IFNɣ signaling in patients who achieved disease control and prolonged survival TURKU, Finland and BOSTON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical co

Related Keywords

Finland , Jukka , Lapland , Boston , Massachusetts , United States , Sandy Jamieson , Mary Jane Elliott , Christopher Golden , Lindsey Neville , David Daley , Juha Karttunen , Petri Bono , Jo Turner , Peel Hunt , Cairn Financial Advisers , Faron Pharmaceuticals Ltd , First North , Cell Reports , Cell Reports Medicine , Chief Medical Officer , Terveystalo Finland , Principal Investigator , Jane Elliott , Certified Adviser , Nasdaq First , Macrophage Activation , Llatins , Disease Control , Faron Pharmaceuticals , Immune Function , Treatment Benefit , Solid Tumors ,